Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles - Alnylam Pharmaceuticals ( NASDAQ:ALNY )
Friday, Alnylam Pharmaceuticals Inc. ALNY stock is trading lower after the company shared detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR amyloidosis with cardiomyopathy ( ATTR-CM ) . Topline data was revealed in June.
| Ticker |
Sentiment |
Impact |
|
ALNY
|
Neutral
|
29 %
|
|
BBIO
|
Neutral
|
29 %
|
|
PFE
|
Somewhat Bullish
|
20 %
|
